Gilead recalls Vistide on particle contamination
February 19, 2013Manufacturing and Production Gilead, Vistide
Gilead Sciences has issued a voluntary recall of one lot of its antiviral treatment Vistide after finding particulate matter in …
CMO plant shut down after Takeda product recall
February 19, 2013Manufacturing and Production CMP, OPG, Takeda
Japan’s regulatory authorities flexed their enforcement muscles last week when it ordered a temporary shutdown of the contract manufacturer for …
ViiV HIV drug boost
February 18, 2013Sales and Marketing Dolutegravir, GSK, HIV, ViiV
ViiV Healthcare has received a boost with the news that the FDA is to give a priority review to its …
Merck makes $688m payout
February 18, 2013Sales and Marketing ENHANCE, Inegy, Merck, Vytorin, investors
Merck has paid out $688 million to end two class-action lawsuits which sprang up after the revelation of disappointing trial …
Another approval for Novartis’ everolimus
February 18, 2013Sales and Marketing Certican, Novartis, Zortress, everolimus
Novartis has gained US approval for its drug Zortress (everolimus) to prevent liver transplant rejection.Zotress is already used to prevent …
Insulin blockbusters targeted by biosimilar blitz
February 15, 2013Research and Development, Sales and Marketing Biocon, Humalog, Mylan, insulin
Mylan and Biocon are the latest companies to announce major new plans to develop and market biosimilars. The firms are …
Janssen launches dementia prize
February 15, 2013Sales and Marketing Hunt, Janssen, NHS, dementia
Janssen has joined forces with the NHS to launch a scheme to financially reward solutions which can help the lives …
Fundraising to fuel e-Therapeutics’ ‘network pharmacology’
February 15, 2013Research and Development e-Therapeutics
Drug discovery and development firm e-Therapeutics hopes to raise £40 million via a new share offer to fund its research …
Lancet sparks agency row
February 15, 2013Medical Communications, Sales and Marketing ABPI, Lancet, Luther Pendragon, Marlboro, Phillip Morris
Communications agency Luther Pendragon has parted company with cigarette firm Philip Morris after attention was drawn to the agency’s other …
Nanobiotix appoints ex-Sanofi head Alain Herrera
February 14, 2013Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, nanobiotix
Nanomedicine firm Nanobiotix has announced that Dr Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun …
BMS hires Ann Powell Judge from Shire
February 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ann Powell Judge, BMS, Shire
BMS has announced that Ann Powell Judge will join the company as senior vice president, Human Resources.From March Judge will …
Shire ADHD drug for UK
February 14, 2013Sales and Marketing ADHD, Shire, Vyvanse, elvanse
Shire’s attention-deficit hyperactivity disorder (ADHD) drug Elvanse has been given the go-ahead for use in the UK. Elvanse (lisdexamfetamine dimesylate), …
Delivering value in cost-constrained healthcare environments
February 14, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, MSI, NHS, VBP, austerity, value
As millions of pounds, euros and dollars are cut from healthcare budgets around the world – driven by austerity measures …
BMS in $438m OTC deal
February 14, 2013Sales and Marketing BMS, Reckitt Benckiser
Bristol-Myers Squibb has signed over the rights to sell, distribute and market half a dozen of its medicines, mainly sold …
Universal WorldEvents creates dedicated training role
February 14, 2013Medical Communications, Research and Development, Sales and Marketing Universal WorldEvents
Event management firm Universal WorldEvents has announced the promotion of Sarah Longland to the new role of senior account manager …
NICE rejects Jakavi
February 13, 2013Sales and Marketing Jakavi, NICE
NICE has today issued draft guidance saying it does not recommend Novartis’ Jakavi for patients with myelofibrosis, a rare blood …
Ironwood announces new president of R&D
February 13, 2013Manufacturing and Production, Research and Development, Sales and Marketing Ironwood
Ironwood Pharmaceuticals has announced the promotion of Mark Currie, to senior vice president, chief scientific officer, and president of research …
Sanofi ups stake in Regeneron
February 13, 2013Sales and Marketing AMD, Regeneron, Sanofi, Zaltrap
Sanofi is increasing its stake in Regeneron Pharmaceuticals by buying shares on the open market and from existing shareholders. The …
Shire pays Impax $48 million
February 12, 2013Sales and Marketing ADHD, Adderall, Impax, Shire
Shire has paid $48 million to settle a long-running legal spat with Impax Laboratories over Shire’s supply of an authorised …
Perrigo buys Rosemont for £180 million
February 12, 2013Manufacturing and Production Perrigo, Rosemont
UK-based Rosemont Pharmaceuticals has been sold by its private equity owner to Perrigo of the US in a £180 million …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
